Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

A potential rally to 6,000 is possible if retail sales are positive and the FOMC Meeting is dovish. Read why investors should ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a four-day winning streak.

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...